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At the end of 2019, a novel coronavirus, SARS-CoV-2, resulted in an 
acute respiratory illness epidemic – COVID-19 – in Wuhan, China.[1] 
The disease rapidly spread globally, and on 11 March 2020 the World 
Health Organization declared the outbreak a pandemic. [2] Since 
identification of the first case of COVID-19 in South Africa (SA) on 
5 March 2020, the number of confirmed cases as of 20 September 
2020 totalled 659 656.[3,4] One in five people with confirmed 
COVID-19 require hospitalisation.[5] In most cases the indication 
for hospitalisation is hypoxaemia requiring supplemental oxygen 
therapy, the duration of which ranges from days to months,[6] putting 
tremendous strain on hospital infrastructure, particularly central 
oxygen supply. Patients hospitalised with COVID-19 have varying 
levels of supplemental oxygen requirements. One strategy that has 
been employed to combat severe COVID-19 respiratory failure and 
hypoxaemia is high-flow nasal oxygen (HFNO).[7] HFNO is a device 
that delivers 30 - 60 L/min of heated and humidified air and oxygen 
blend at the desired fraction of inspired oxygen (FiO2) via a wide-bore 
nasal cannula.[8] This method reduces anatomical dead space, work 
of breathing and respiratory rate, while increasing positive pressure 
and compliance.[8]
At Groote Schuur Hospital (GSH), a tertiary referral hospital in 
Western Cape Province, SA, 343 patients admitted with COVID-19 
acute hypoxic respiratory failure from 7 May to 26 August 2020 have 
been treated with HFNO in dedicated COVID-19 high-care wards. 
With up to 34 HFNO machines simultaneously operational in these 
wards during the peak of the pandemic, and most patients requiring 
flow of 60 L/min and FiO2 upwards of 90%, sufficient and reliable 
central oxygen supply was, and continues to be, essential. Reliable 
central oxygen supply at healthcare facilities is a particular problem 
in resource-constrained sub-Saharan African settings, making 
the upscaling of HFNO as a potentially beneficial intervention 
challenging.[9]
In this report, we present a case of prolonged and ultimately 
successful treatment of COVID-19 pneumonia treated successfully 
with HFNO.
Case report
A 55-year-old, obese (BMI 32 kg/m2) non-smoking woman, 
previously well, was referred to our tertiary hospital with COVID-
19 pneumonia. She had been diagnosed on a nasopharyngeal swab 
that was reverse transcriptase polymerase chain reaction-positive 
for SARS-CoV-2 after presenting to her local district hospital 
with a 1-week history of myalgia, fever, dry cough and progressive 
worsening shortness of breath. Fig. 1 shows the admission chest 
radiograph. Her only previous illness was pulmonary tuberculosis 
in childhood, successfully treated, and she had grown up in a rural 
settlement in Eastern Cape Province with significant indoor biomass 
fuel smoke exposure. Her referral to our hospital was triggered 
by increasing oxygen requirements over a 5-day period, no longer 
maintaining saturations of ~92% on pulse oximetry on a non-
rebreather reservoir face mask.
On examination, the patient was in marked respiratory distress 
in the prone position, and unable to complete full sentences owing 
to breathlessness. Table 1 presents arterial blood gas measurements 
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prior to HFNO and Table 2 admission vital signs. The admission team 
immediately transferred her to a dedicated COVID high-care ward, 
and initiated HFNO at 60 L/min with FiO2 95%. She was reassessed 
closely for 6 hours, during which time her condition stabilised. 
Intermittent awake prone positioning continued (Table 2), and 
ongoing management was framed around five main areas: oxygenation, 
anticoagulation, steroid provision, management of complications, and 
multidisciplinary psychosocial support. 
Oxygenation
The patient required HFNO for a total of 40 days, with additional 
standard oxygen support for a further 16 days. She elected to remain 
predominantly in the prone position for the first 32 days owing to 
profound desaturation with even the slightest movement, and required 
an FiO2 of >90% for the first 20 days. At this point, it was possible 
to wean the FiO2 gradually over several days (Fig. 2 shows HFNO 
settings over time). On day 36 of HFNO, she was able to mobilise 
from her bed to a chair for the first time. On day 40 of HFNO, she 
was successfully transitioned to a 40% Venturi face mask, on which 
she remained for a further 8 days, and thereafter transitioned to 
conventional nasal prong oxygen (NPO2) at 4 L/min. After 8 days 
on NPO2 she was able to spend short periods of the day on room air 
alone. A full 56 days after admission, she was able to mobilise without 
supplementary oxygen.
Anticoagulation
Following admission to GSH, enoxaparin 1 mg/kg subcutaneously 
twice daily was continued. On day 25 on HFNO the patient was 
noted to have developed a spontaneous haematoma in her right 
thigh. The anti-factor Xa level was supratherapeutic at 1.87. Her 
enoxaparin dose was reduced according to serial anti-factor Xa 
levels. The surgical team was consulted, and the decision was made 
to manage the haematoma conservatively. The haematoma resolved 
without complication. Twice-daily enoxaparin at the adjusted dose 
was continued for the duration of her hospitalisation. In the last 
week of her hospitalisation, a computed tomography (CT) scan of her 
pulmonary arteries was performed to assess the presence of ongoing 
thrombosis to guide our anticoagulation strategy after discharge. The 
CT scan found no evidence of thromboembolic disease, only the 
typical bilateral, multifocal ground-glass opacification of COVID-19 
pneumonia. The enoxaparin was subsequently stopped on discharge, 
with no outpatient anticoagulation prescribed.
Steroids
Dexamethasone 6 mg intravenously daily was continued for 3 days 
after admission to GSH. On day 4 on HFNO, the intravenous 
cannula was removed, and prednisone 40 mg orally daily was 
commenced. This dosage of prednisone was continued for the 
Fig. 1. Admission chest radiograph at the district hospital.
Table 1. Arterial blood gas measurements before HFNO 




Standard bicarbonate (mmol/L) 28.3
Lactate (mmol/L) 1.8
P:F ratio (mmHg) 25
HFNO = high-flow nasal oxygen; pO2 = partial pressure of oxygen; pCO2 = partial pressure 
of carbon dioxide; P:F ratio = arterial pO2/FiO2; FiO2 = fraction of inspired oxygen.
Table 2. Vital signs pre and post HFNO initiation at Groote Schuur Hospital
Pre HFNO (non-rebreather reservoir 
face mask at 15 L/min) (prone)
6 hours post HFNO initiation (FiO2 93%,  
flow rate 60 L/min) (prone)
Heart rate (bpm) 120 115
Respiratory rate (breaths per minute) 48 36
Peripheral oxygen saturation (%) 65 94
Temperature (oC) 37.8 37
Blood pressure (mmHg) 136/77 150/80
ROX index 1.59 2.81















































































Figure 2 HFNO settings over time
FiO2 (%) Flow (/min)
Fig. 2. HFNO settings over time. (HFNO = high-flow nasal oxygen; FiO2 = 
fraction of inspired oxygen.)
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duration of her time on HFNO and subsequently gradually weaned 
to a stop by discharge.
Management of complications
On day 29 of HFNO, a deterioration in the patient’s condition 
was noted. She developed a low-grade pyrexia of 37.4oC, her 
respiratory rate climbed from 24 to 34 breaths per minute, and she 
developed a new-onset sinus tachycardia of 140 bpm. A thorough 
diagnostic evaluation for infection ensued. On enquiry, the patient 
only reported worsening breathlessness without any other specific 
symptomatology. Thorough examination revealed no obvious 
source of infection or COVID-19-related complications. The only 
remarkable feature elicited was new-onset bilateral coarse crackles 
upon lung auscultation. There were no clinical features of fluid 
overload. Urinalysis was unremarkable, a blood culture was drawn, 
and a chest radiograph showed diffuse, bilateral patchy ground-
glass opacities. Empirical antibiotics were initiated for suspected 
nosocomial pneumonia (piperacillin-tazobactam 4.5 g intravenously 
6-hourly for 5 days and amikacin 1 g intravenously daily for 3 days). 
Blood culture and urine culture showed no growth. Her renal 
function remained normal, troponin T was not raised, and her 
anti-Xa level was therapeutic. Over the course of the next 3 days she 
recovered and completed the course of antibiotics.
Multidisciplinary psychosocial support
Multidisciplinary input was required to complete our comprehensive 
package of care. The patient was nursed in a high-care ward where 
a dedicated team of nursing staff worked tirelessly to care for her. 
Our dietetics team reviewed her regularly and provided daily 
nutritional supplementation. On day 30 on HFNO, she developed 
a number of mental health symptoms, including feeling sad, tired 
and overwhelmed, anxious and helpless. Prior to this she had 
demonstrated remarkable resilience despite the length of her hospital 
stay and the severity of her symptoms. Psychiatry provided ongoing 
counselling and advised the initiation of citalopram 20 mg when her 
mental health symptoms, particularly her anxiety, negatively affected 
her HFNO weaning process. She responded well to the combination 
of citalopram and supportive counselling and thereafter was able to 
engage well with her transition to facemask oxygen. The social work 
team was also involved in managing her prolonged absence from 
work. Upon discharge, she was given a temporary disability grant to 
tide over the rest of her recovery.
Sixty-nine days after presenting to her local district hospital the 
patient was discharged home, mobilising freely without the need 
for supplemental oxygen. She received pneumococcal and influenza 
vaccines prior to discharge.
Discussion
The case described is remarkable in that it highlights incredible 
resilience on the part of the patient and dedication on the part of the 
treating multidisciplinary team. It is also striking to note the volume 
of oxygen consumed during her treatment course.
In a cohort of 293 patients with COVID-19 hypoxic respiratory 
failure enrolled at GSH and Tygerberg Hospital (TBH) during the 
pandemic, the median (interquartile range) time on HFNO in those 
successfully weaned was 6 (3 - 9) days.[10] The 40 days described 
above is the longest time any patient has spent on HFNO in this 
cohort – by a considerable margin. We have been unable to find 
another case of HFNO used for this duration before in a patient 
with a good outcome. There are no randomised trials of early v. late 
intubation for patients on HFNO, and we do not know whether this 
patient’s dependence on oxygen would have been reduced with early 
intubation and ventilation. At GSH during the peak of the pandemic, 
the capacity to treat the numbers of patients with hypoxic respiratory 
failure with ventilation in the intensive care unit (ICU) was severely 
constrained.[11] HFNO was used as an alternative to try to overcome 
limited ICU resources. In the cohort from GSH and TBH, it was 
shown that in a resource-constrained setting, HFNO for COVID-19 
hypoxic respiratory failure is feasible even outside the ICU and averts 
death or the need for mechanical ventilation in almost half of those 
who receive it.[10]
Over the course of our patient’s 40 days on HFNO, she averaged 
an FiO2 of 77% at a flow rate of 52 L/min. This equates to the 
consumption of 40 L of gaseous oxygen per minute or a total of 
2.3 million L of gaseous oxygen over the 40 days. Central oxygen is 
supplied in the liquid form. One litre of liquid oxygen weighs 1.14 kg 
and equates to 861 L of gaseous oxygen at one standard atmosphere 
and 21oC.[12] Therefore, 2 678 L or 3.05 tons of liquid oxygen was 
required to meet her oxygen needs while on HFNO. At our hospital 
prior to the COVID-19 pandemic, liquid oxygen was stored in two 
tanks, one holding 5 tons of liquid oxygen and the other 4 tons. 
In March 2020, in preparation for the anticipated surge in oxygen 
requirement, a larger 20-ton tank was installed (Fig. 3). During July 
2020, at the peak of the COVID epidemic, oxygen consumption at 
GSH peaked at consumption of 8 tons of liquid oxygen a day.
Caring for this patient was significantly less costly, easier and 
associated with fewer complications than if she had been admitted 
to an ICU or ventilated. She was nursed in a six-bed cubicle in an 
open ward, with minimal extra staff allocated to her care. She was 
able to feed and prone herself, move her nasal interface, and use a 
bedpan with minimal assistance. Hospital complications for such 
an ill patient were minimal because of the use of HFNO – she was 
awake, developed no bedsores or other complications possible in 
Fig. 3. Oxygen storage tanks at Groote Schuur Hospital.
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sedated patients, and required no ongoing intravenous access (with 
its possible complications of drip-site sepsis).
Despite the large amount of oxygen used, costs for this inpatient 
treatment were relatively low. Oxygen supply to GSH is currently 
priced at ZAR8.73/kg liquid oxygen. An approximated cost analysis 
of this patient’s oxygen consumption equates to ZAR26 600 while 
on HFNO. Oxygen for healthcare use is a finite, albeit replenishable, 
resource. HFNO consumes oxygen to a greater extent than other 
methods of respiratory support, and facility assessment and 
preparation for increased demands should be considered when 
planning for COVID-19 hospital readiness. Ongoing assessment of 
on‐site oxygen supplies and robustness of the oxygen supply chain 
should be a strategy to prevent and troubleshoot oxygen supply 
problems.
COVID-19 has rapidly become a global health emergency, 
resulting not only in physical health concerns but also psychological 
stress, as patients and families are exposed to the risk of premature 
death. Patients admitted to hospital with COVID-19 experience 
social isolation (particularly as families and visitors are not permitted 
in wards), physical discomfort, and fear of dying. The psychological 
impact of being surrounded by critically ill patients cannot be 
overstated. Over the 40-day period during which our patient was 
on HFNO, 183 other patients were initiated on HFNO in the 
high-care wards; 13% of this group died in the high-care wards, 
35% were intubated, 40% were successfully weaned off HFNO and 
discharged, and the rest were still receiving HFNO at the time she 
was successfully weaned onto face-mask oxygen. It was incredibly 
challenging to be repeatedly exposed to fellow patients deteriorating 
around her, and perhaps even more challenging to see so many 
go home to their families while she was confined to the ward, 
dependent on oxygen. Despite these overwhelming circumstances, 
the patient showed remarkable resilience and ability to cope with 
stress. She enthusiastically used all the resources made available 
to her, communicated openly about her experience, and formed 
warm relationships with the multidisciplinary team. This is indeed a 
narrative of oxygen and resilience.
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